Our start-up portfolio
We've built an incredible production line for start-up companies to bring early-stage technologies out of the research lab and translate them into patient benefit. Our start-up portfolio secures funding from investors around the world who believe in our world class science and the power of partnership.
79
start-ups formed across therapeutics, diagnostics and medtech
23
start-up exits to date
£3bn
raised by our start-up portfolio
Infinitopes £12.8m Seed financing
Featured start-up
“This fundraise enables us to pursue our uniquely integrated strategy of selecting the right targets, with the right vectors, for the right patients, at the right time in their treatment journey.”
-Jonathan Kwok, CEO and Co-founder of Infinitopes
Infinitopes is leading the cancer vaccine revolution. Cancer Research Horizons invested in its oversubscribed Seed funding round alongside Octopus Ventures, Cancer Research Institute, CRIS Cancer Foundation, Kindred Capital, Manta Ray, Martlet Capital, Meltwind Advisory, Saras Capital, Wilbe Capital, and expert angel investors, to support the progression of its lead asset into the clinic.
Myricx Bio’s £90m Series A financing to advance ADCs to the clinic
A founder's perspective
“We are now well positioned to build on our NMTi ADC platform and advance our pipeline as we become a clinical stage company.”
-Robin Carr, CEO of Myricx
Myricx is pioneering the next generation of ADCs with a novel class of payload. Having supported the start-up and its leadership for several years, Cancer Research Horizons joined its Series A financing, one of Europe’s largest Series A funding rounds of the year, alongside leading life science investors Novo Holdings, Abingworth, Brandon Capital, Sofinnova Partners, British Patient Capital, and Eli Lilly.
Let's go further, faster, together
Find out how to invest in one of our portfolio companies or get support to start your own.